Open company graph database — free web & API
Login

Takeda Pharmaceuticals U.S.A., Inc.

Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
2
§01

Basic information

BASIC
Head office
540-8645 Osaka City, Chuo Ward, Doshomachi 4-1-1
Chief executive
Christophe Weber
Capital
1,676,300,000,000 JPY (16,763 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
Start date
1925-01-29
End date
§02

Websites

1 DOMAINS
§03

Business

6
Research and development of pharmaceuticalsManufacturing of pharmaceuticalsSales of pharmaceuticalsConducting clinical trialsPromotion of open innovationResearch, development, manufacturing, sales, import and export of pharmaceuticals, etc.
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Takeda Pharmaceutical Company, Limited
Group Parent
Calmedica
Supplier
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

122 EVENTS

On May 20, 1946, Takeda opened the Hikari Factory in Hikari City, Yamaguchi Prefecture, on the site of the former Imperial Navy factory.Sources

Diphtheria and Typhoid vaccines began production in July 1946.Sources

The diphtheria and typhoid vaccine was first shipped in January 1947, becoming the first pharmaceutical product shipped from the Hikari Factory.Sources

Japanese Encephalitis vaccine production began in 1954.Sources

The antibacterial substance production facility was completed in June 1954.Sources

Production of antibacterial substances started in July 1954.Sources

The Vitamin C plant was completed in 1961 and production started.Sources

Post-war, the demand for Vitamin C was high worldwide. A large Vitamin C manufacturing plant was built at the Hikari Factory, equipped with a central control room and adopting a centralized control system, making it a highly advanced plant for its time.Sources

Vitamin B1 plant was completed and production started.Sources

Alicin, a component of garlic, is converted into a Vitamin B1 derivative. The product Arinamin was launched in 1954, sold domestically and internationally, with the Hikari Factory establishing new manufacturing lines for increased production.Sources

Vitamin C second plant was completed and production started.Sources

The demand for vitamin C is increasing, and the Kō factory expanded its vitamin C manufacturing plant to meet this. A second plant with about four times the capacity of the first plant completed in 1961 was built. In 1973, a third plant was also established. Each time a new plant was built, the latest technology was introduced, advancing continuous and automated processes.Sources

The dried attenuated measles vaccine is the first product manufactured at the Hikari Factory. It uses a weakened virus that has lost its pathogenicity, which proliferates in the body to stimulate immunity.Sources

The dried attenuated measles vaccine is the first product manufactured by the Kō factory using live vaccine. This highly technical live vaccine is made from a virus that has been weakened and lost its pathogenicity. The virus proliferates within the body, boosting immunity.Sources

In the late 1960s to early 1970s, Japan faced serious environmental issues due to industrialization and urbanization. Laws such as the Basic Law for Environmental Pollution Control (1967) were enacted. The Hikari Factory established an environmental department and installed equipment to prevent air and water pollution, also taking measures to prevent noise and odors, protecting the surrounding natural environment.Sources

In Japan from the late 1960s to early 1970s, industrialization and urbanization led to serious environmental issues, prompting the enactment of laws such as the Basic Law for Environmental Pollution Control (1967). The Kō factory established an environmental department and installed equipment to prevent air pollution and water contamination. Activities to protect the surrounding natural environment continue to this day, including measures against noise and odors.Sources

Penicillin, used to treat bacterial diseases such as pneumonia and syphilis, was traditionally purified using fermentation technology. The Kō factory produced the penicillin-based antibiotic 'Lirasillin,' which was manufactured through chemical synthesis rather than fermentation. This was Japan's first synthetic penicillin, contributing to many patients in need and becoming a main product of Takeda.Sources

Both Cefothiam hydrochloride and Cefuroxime sodium are cephalosporin antibiotics. Cefothiam hydrochloride was produced in a large-scale factory due to high demand. Cefuroxime sodium was the first antibiotic at Takeda to pass FDA inspection for injectable drugs.Sources

'Cefothiam hydrochloride' and 'Cefslozin sodium' are antibiotics called cephamycin antibiotics. These drugs inhibit bacterial cell wall synthesis, exerting bactericidal effects. 'Cefothiam hydrochloride' was produced in a large-scale factory due to high demand. 'Cefslozin sodium' was the first antibiotic from Takeda to pass FDA inspection for injectable drugs.Sources

New manufacturing facilities for powdered antibiotic injections were completed, producing drugs like 'Cefslozin sodium' and 'Cefmenoxime hydrochloride.' This new plant established systems for sterile manufacturing, quality control, and testing.Sources

Manufacturing equipment for powdered antibiotic injections was completed and production started. This included drugs like Cefslozin sodium and Cefmenoxime hydrochloride, establishing systems for sterile manufacturing, quality control, and testing.Sources

In 1985, established TAP Pharmaceuticals Inc. (later TAP Pharmaceuticals Products Inc., split in 2008 and merged with Takeda Pharmaceuticals North America Inc.) as a joint venture with Abbott in the United States. Same year, launched the prostate cancer treatment drug 'Lupron (generic name: Leuprorelin)', developed in-house.Sources

In 1985, launched Lupron with DDS (drug delivery system) research results, a depot formulation of Leuprorelin that lasts for one month with a single injection. Currently sold in about 80 countries worldwide, it has become a standard drug for prostate cancer treatment. A formulation that can sustain treatment effects for up to four months with a single injection is also available in the US.Sources

Leuprorelin acetate, used for treating endometriosis and prostate cancer, was launched in 1985. Due to increasing demand domestically and internationally, mass production began at the Kō factory. Other drugs such as Lansoprazole, Candesartan, and Pioglitazone also began sales overseas, increasing demand for the factory.Sources

Leuprorelin acetate, used for treating endometriosis and prostate cancer, was launched in 1985. Mass production at the Kō factory began due to rising demand domestically and abroad.Sources

The safety evaluation system for drugs was further strengthened. As candidate substances increased, the safety evaluation system at the research institute was expanded. A branch of the Drug Safety Research Institute was established within the Kō factory, responsible for long-term safety testing, ensuring rapid and reliable data, and improving safety assessment capabilities.Sources

The safety evaluation system was further improved by establishing a branch of the Drug Safety Research Institute within the Kō factory, responsible for long-term safety testing and enhancing safety assessment capabilities.Sources

In 1989, launched a 1-month depot formulation of Leuprorelin (generic name) in the US and Europe.Sources

In 1989, launched a 1-month depot formulation of Leuprorelin (generic name) in the US and Europe.Sources

Production of Leuprorelin acetate, a gonadotropin-releasing hormone analog developed in-house, began. It is used for treating endometriosis and prostate cancer domestically and internationally.Sources

Production of Leuprorelin acetate, a gonadotropin-releasing hormone analog developed in-house, began. It is used for treating endometriosis and prostate cancer domestically and internationally.Sources

In 1991, launched the anti-ulcer drug Lansoprazole (generic name) in Europe. Started sales of the company's proprietary proton pump inhibitor Lansoprazole (generic name) in Europe, Japan, Asia, and the US. Currently sold in about 90 countries worldwide.Sources

Production of Lansoprazole, a proton pump inhibitor developed in-house, began. It is used for treating peptic ulcers both domestically and internationally.Sources

Started production of our proprietary proton pump inhibitor "Lansoprazole." It is used domestically and internationally for treating peptic ulcers.Sources

New equipment for manufacturing cephalosporin antibiotics like Cefozupran hydrochloride using freeze-drying technology was installed.Sources

We have newly established manufacturing equipment for the cephalosporin antibiotic "Cefozopran Hydrochloride," produced using freeze-drying technology in powder form.Sources

In 1995, established L.I. Takeda, a special subsidiary aimed at employing people with disabilities, under the management philosophy of 'A company that loves working people with disabilities'—the first in the pharmaceutical industry.Sources

The bulk manufacturing equipment for Leuprorelin acetate was completed.Sources

In response to increased demand for the once-every-four-weeks injectable formulation of "Leuprorelin Acetate," we have expanded our active pharmaceutical ingredient production facilities.Sources

We have installed new equipment to increase the production of raw materials due to rising sales volume.Sources

Started production of our proprietary angiotensin II receptor antagonist "Candesartan." It is used domestically and internationally for hypertension treatment.Sources

To accelerate decision-making and improve organizational strength, we introduced a company system. The large-scale food and vitamin manufacturing division at Hikari Plant was renamed "Food and Vitamin Company Hikari Manufacturing Division," the Agro Manufacturing Division was renamed "Agro Company Hikari Manufacturing Division," and the Tokuyama Plant was renamed "Chemical Products Company Tokuyama Factory," separating from Hikari Plant.Sources

On May 20, a ceremony commemorating the 50th anniversary of Hikari Plant was held. As part of the event, a donation was made to Hikari City for community contribution. Additionally, as part of the commemorative project, all employees planted one Ubamegashi tree each, totaling 1,776 trees, on the coastal reclamation site, and the mayor of Hikari City and other guests planted 22 trees in the Hikari Plant courtyard, promoting environmental conservation and greening efforts in collaboration with Hikari City.Sources

In 1997, launched the antihypertensive drug Candesartan Cilexetil (generic name) in Europe. Began sales of the company's proprietary Candesartan Cilexetil (generic name) in the UK and Germany. As an angiotensin II receptor antagonist creating a new trend in hypertension treatment, it is now sold in about 60 countries worldwide.Sources

In 1997, established Takeda Limited, a wholly owned pharmaceutical sales company in the UK.Sources

In 1997, established Takeda Ireland Limited, a pharmaceutical manufacturing plant.Sources

In 1997, established Takeda America Research and Development Center Inc. in the US.Sources

In 1997, established Takeda America Holdings Inc., a holding company for the pharmaceutical business in the US.Sources

In 1998, established Takeda Pharmaceuticals America Inc. as a wholly owned sales base in the US. Started sales of the company's proprietary type 2 diabetes drug Actos from the following year.Sources

In 1998, established Takeda Europe Research and Development Center Inc. (now Takeda Global Research and Development Center Europe Inc.).Sources

Obtained certification for the environmental management system "ISO14001."Sources

In 1999, launched the diabetes treatment drug Actos (generic name: Pioglitazone). The company's proprietary insulin resistance improving drug Actos was launched in the US and Japan, followed by sales in Asia and Europe the following year.Sources

Started production of our proprietary insulin resistance improving drug "Pioglitazone." It is used domestically and internationally for diabetes treatment.Sources

In 2000, the restructuring of the pharmaceutical external business began. By 2006, the restructuring of the animal drug business, vitamin business, chemical products business, food business, agricultural chemicals business, and lifestyle environment business was carried out.Sources

From 2001 onward, efforts to reduce greenhouse gas emissions.Sources

In 2002, acquired management rights of Takeda Pharma GmbH and established Takeda Ireland Pharmaceuticals Ltd., a manufacturing plant for active pharmaceutical ingredients.Sources

Integrated the US biotech venture Syrix, incorporated it into our global research and development network, and renamed it Takeda San Diego Inc. Syrix possesses high-speed X-ray crystallography technology for proteins, and this integration marked our first research base in the US.Sources

Rozerem (generic name: Ramelteon) is a melatonin receptor agonist that induces natural-like physiological sleep, different from traditional insomnia treatments. It provides sleep without anxiolytic or sedative effects.Sources

To strengthen our business foundation in Europe, a sales management company was established in London, UK, to comprehensively manage Takeda Group's sales companies in six European countries.Sources

As a culmination of strengthening US operations from the mid-1970s and a foundation for further presence in the US, Takeda Pharmaceuticals North America Inc. and Takeda Global Research and Development Center Inc. completed their new headquarters buildings.Sources

Our company issues an annual report as an integrated report that includes non-financial information such as human rights, environment, and community initiatives, in addition to financial data. The CSR Data Book is a detailed re-edition of the annual report, providing further explanation of non-financial information.Sources

Integrated UK-based Paradigm Therapeutics and its Singapore subsidiary to enhance and strengthen our multi-IND engine. Paradigm Therapeutics was founded in 1999 by researchers at Cambridge University and aligns with many of our focus disease areas. The company and its Singapore subsidiary have been renamed Takeda Cambridge Inc. (TCB) and Takeda Singapore Inc. (TSP), respectively.Sources

Based on an agreement with Abbott, the company split TAP, which became a wholly owned subsidiary. In July of the same year, TAP was merged into Takeda Pharmaceuticals North America Inc. (TPNA), and its development functions were consolidated into Takeda Global R&D Center Inc. (TGRD).Sources

Millennium is one of the world's leading biopharmaceutical companies with a strong pipeline in oncology. It is a pioneer in protein homeostasis research, developing innovative drug targets. The company's expertise in oncology complements ours, creating significant synergy.Sources

Established Takeda Pharmaceuticals Asia Inc. and Takeda Clinical Research Singapore Inc.Sources

Conversion of energy fuels and efforts to reduce greenhouse gas emissions.Sources

In 2008, the "Kyoto Protocol" set greenhouse gas reduction targets. At Hikari Plant, efforts to reduce carbon dioxide emissions, a type of greenhouse gas, included switching fuel from heavy oil to city gas, resulting in significant reductions.Sources

In the 2008 Kyoto Protocol, greenhouse gas reduction targets were set. The Hikari plant aimed to reduce CO2 emissions, a type of greenhouse gas, by switching fuel from heavy oil to city gas, achieving significant reductions.Sources

Integrated Takeda Ireland Ltd., a manufacturing and packaging plant, in 2009.Sources

Dexlansoprazole (generic name: Dexlansoprazole) is a proton pump inhibitor with a unique dual-release formulation that provides powerful and sustained suppression of gastric acid secretion.Sources

Urolic (generic name: Febuxostat) is a treatment for gout and hyperuricemia developed by Teijin Pharma. It inhibits uric acid synthesis enzyme, showing excellent uric acid lowering effects.Sources

Supports the 10 principles of human rights, labor, environment, and anti-corruption, integrating them into all corporate activities. A dedicated CSR organization has been established to enhance CSR activities.Sources

Received the "PRTR Award 2008 Grand Prize" for chemical substance management and risk communication initiatives.Sources

Achieved zero emissions aimed at waste reduction and increased recycling rates.Sources

Received the 'PRTR Grand Prize 2008' for excellence in chemical substance management and risk communication efforts.Sources

Achieved zero emissions with the goal of waste reduction and improved recycling rates.Sources

The company supports activities to improve healthcare access in developing countries from a long-term, sustainable perspective. Since 2010, a 10-year donation program called 'Takeda Initiative' has been implemented to develop healthcare personnel in three African countries through the Global Fund to Fight AIDS, Tuberculosis and Malaria. For example, in Nigeria, over 11,000 teachers received training in 2012, reaching over 1.2 million students, contributing to a decline in HIV-positive rates among youth.Sources

Our company has established the "Takeda Global Code of Conduct" as a basic compliance rule shared across the group companies to promote more unified global business operations.Sources

Participated in the 30 million Seto Inland Sea Cleanup Campaign. Employees of Hikari Plant participated in activities such as cleaning rivers and beaches around the Seto Inland Sea.Sources

Received the Minister of Health, Labour and Welfare Award for contributions to promoting reduce, reuse, and recycle efforts.Sources

Employees of the Hikari plant participated in activities such as cleaning rivers and beaches around the Seto Inland Sea, involving local companies and organizations.Sources

Received the Minister of Health, Labour and Welfare Award for efforts in promoting reduce, reuse, and recycling.Sources

Azilva (generic name: Azilsartan) is a new angiotensin II receptor antagonist (ARB). Clinical trials have confirmed its superior blood pressure-lowering effect compared to existing ARBs.Sources

The Shonan Research Institute was created by integrating the Osaka Juso Research Institute and the Tsukuba Research Institute. It is a global research hub accelerating drug discovery innovation, with about 1,200 researchers working on early-stage drug discovery, candidate compound selection, and non-clinical studies from drug target exploration to market launch.Sources

In September 2011, we completed the integration of Swiss pharmaceutical company Nykomed. Nykomed is a prominent company in Europe and emerging markets, and this integration expanded Takeda's sales network to over 70 countries, enhancing our sales system and expertise to deliver medicines to more patients and healthcare professionals worldwide.Sources

Since January 2011, our company has been a member of the UN Global Compact's "LEAD Program," leading activities to promote and practice the 10 principles of "Human Rights," "Labor," "Environment," and "Anti-Corruption" alongside about 60 global companies.Sources

A part of Arinamin's revenue is donated to support the long-term and continuous reconstruction of areas affected by the Great East Japan Earthquake.Sources

Held an in-house market supporting the reconstruction of the Great East Japan Earthquake. To support the affected areas, local specialties from Tohoku and Kanto regions were sold to employees at Hikari Plant.Sources

Started production of our proprietary angiotensin II receptor antagonist "Azilsartan." It is used domestically and internationally for hypertension treatment.Sources

Held an 'in-house market' to support the reconstruction of the affected areas of the Great East Japan Earthquake. The event sold local specialties from Tohoku and Kanto regions to employees.Sources

Started production of the company's own angiotensin II receptor antagonist 'Irbesartan'. It is used as a treatment for hypertension both domestically and internationally.Sources

Sources

Adcetris (generic name: Brentuximab Vedotin) was launched in Europe (2012) and Japan (2014). It is a medicine offering new treatment options for patients with rare diseases such as relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.Sources

WEPs are a set of voluntary business principles for gender equality, jointly developed by the UN Global Compact and UN Women. Our company signed a support statement in December 2012 and aims to accelerate the creation of an environment and talent development to make women shine, based on the seven principles of WEPs.Sources

Lotriga (generic name: Omega-3 fatty acid ethyl ester) is a high-concentration omega-3 fatty acid preparation introduced by Pronova. It is the first medical drug in Japan containing both EPA and DHA.Sources

Nesina (generic name: Alogliptin benzoate) is a type 2 diabetes treatment developed by Takeda California Inc., which lowers blood sugar by inhibiting the enzyme DPP-4 that breaks down the hormone glucagon-like peptide-1 (GLP-1), which enhances insulin secretion.Sources

The integration of Inviragen Inc. (USA) has enhanced our global vaccine market presence by acquiring innovative pipeline and live and inactivated vaccine platform technologies.Sources

Trintellix, an adult depression treatment introduced from Denmark's Lundbeck, is expected to contribute to depression treatment with its different pharmacological action. The product name was changed from Brintellix to Trintellix in 2016.Sources

Established a disaster prevention center to serve as a base for disaster response activities during large-scale disasters. It is also used as a stockpile base for supplies needed for disaster relief.Sources

Started production of our proprietary proton pump inhibitor "Benoprazan Fumarate." It is used for treating acid-related diseases.Sources

Established a disaster prevention center as a base for disaster response activities in case of large-scale disasters. It is also used as a stockpile base for supplies needed for victim rescue.Sources

Started production of the company's own proton pump inhibitor 'Vonoprazan Fumarate'. It is used for the treatment of acid-related diseases.Sources

Adcetris (generic name: Brentuximab Vedotin) was launched in Europe (2012) and Japan (2014). It is a new treatment option for patients with relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.Sources

The novel influenza that emerged around the United States and Mexico in April 2009 also spread within Japan during the summer of the same year. At that time, domestic vaccine production could not keep up, and the company, Takeda, which had withdrawn from the influenza vaccine business, resumed manufacturing at the Hikari plant to contribute to stable supply. An application for manufacturing and sales approval was submitted in March 2013, and approval was obtained in April of the following year.Sources

The novel influenza that emerged around the United States and Mexico in April 2009 also spread within Japan during the summer of the same year. At that time, domestic vaccine production could not keep up, and the company, Takeda, which had withdrawn from the influenza vaccine business, resumed manufacturing at the Hikari plant to contribute to stable supply. An application for manufacturing and sales approval was submitted in March 2013, and approval was obtained in April of the following year.Sources

Entyvio (generic name: Vedolizumab) is a groundbreaking product providing new treatment options for patients with inflammatory bowel disease who did not respond to existing therapies. It was launched in Europe and the US in June 2014.Sources

Ninlaro, a multiple myeloma treatment, was launched in the US in 2015 as the world's first oral proteasome inhibitor. It is based on Nobel Prize-winning science and decades of research on multiple myeloma.Sources

Takeda and Kyoto University’s iPS Cell Research Institute (CiRA) have launched the joint research program T-CiRA for clinical application of iPS cell technology.Sources

Ninlaro, a multiple myeloma treatment, was launched in the US in 2015 as the world's first oral proteasome inhibitor.Sources

Ariad Pharmaceuticals was merged. This integration allowed Takeda to add solid cancer to its global portfolio and strengthen its oncology pipeline.Sources

Started production of the biological drug 'Bevacizumab (Recombinant DNA)'. It is used as a treatment for inflammatory bowel disease both domestically and internationally.Sources

Started production of the biological drug 'Bevacizumab (Recombinant DNA)'. It is used as a treatment for inflammatory bowel disease both domestically and internationally.Sources

Shonan Health Innovation Park (Shonan i-Park) is Japan's first ecosystem led by a pharmaceutical company, creating the latest healthcare solutions in an open and innovative environment.Sources

The Takeda Global Headquarters (Tokyo) was grandly opened. It is designed to be a workplace that fosters diverse working styles and creative work.Sources

Takeda became the only pharmaceutical company listed on both the Tokyo Stock Exchange and NYSE.Sources

At the time of approval for manufacturing and selling the 2014 new influenza vaccine, the Hikari plant had equipment capable of producing 25 million doses. In 2015, an additional 8 million doses were decided to be produced, prompting the start of production system improvements. The expansion was completed in 2018.Sources

Consolidated manufacturing and packaging of solid formulations at the Hikari plant.Sources

At the time of approval for manufacturing and selling the 2014 new influenza vaccine, the Hikari plant had equipment capable of producing 25 million doses. In 2015, an additional 8 million doses were decided to be produced, prompting the start of production system improvements. The expansion was completed in 2018.Sources

Shire was merged. Takeda becomes a global leading research and development bio-pharmaceutical company with bases in approximately 80 countries and regions.Sources

TAKEDA LIFE THEATER was opened. It is located on the first floor of Takeda Global Headquarters and contributes to community healthcare and health promotion.Sources

In response to the global pandemic of COVID-19, Takeda is responsible for the rapid import and domestic distribution under strict temperature control of vaccines approved through clinical trials in Japan. Additionally, Takeda has built and is preparing to operate its own COVID-19 vaccine manufacturing facility. The production line, transferred from U.S. pharmaceutical company Novavax, utilizes biotechnologies cultivated at the Hikari plant.Sources

The novel coronavirus disease (COVID-19) has shown a global pandemic. We are responsible for the rapid import of vaccines that have received pharmaceutical approval after clinical trials in Japan, and for domestic distribution under strict temperature control. Furthermore, Takeda is building and preparing to operate its own manufacturing facilities for COVID-19 vaccines. The manufacturing line, which was developed through technology transfer from U.S. pharmaceutical company Novavax, utilizes biotechnologies cultivated in our light manufacturing plants.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑